2 November 2023
Latham & Watkins Advises IDEAYA Biosciences in Public Offering
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| John Williams Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Eric Hanzich | Latham & Watkins LLP | Associate | corporate | Orange County |
| Tiana Baghdikian | Latham & Watkins LLP | Associate | corporate | Orange County |
| Caitlin Nguyen | Latham & Watkins LLP | Associate | corporate | Orange County |
| Amy Lutfi | Latham & Watkins LLP | Associate | corporate | Orange County |
| Christopher Hazuka | Latham & Watkins LLP | Partner | intellectual property and technology transactions | Bay Area |
| James Metz | Latham & Watkins LLP | Partner | employee benefits and compensation | Bay Area |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Rasha Suleiman | Latham & Watkins LLP | Associate | tax | Not stated |
| John Manthei | Latham & Watkins LLP | Partner | FDA regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | FDA regulatory | Bay Area |
| Amy Speros | Latham & Watkins LLP | Counsel | FDA regulatory | Washington, D.C. |
| Kiera Murphy | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
Stated terms
- Stated value
- USD 144m (approximately US$143.8 million)
- What the figure measures
- Issue size
- Client
- IDEAYA Biosciences, Inc.Issuer
- Counterparties
- Not stated